|
[1]
|
Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia
DARU Journal of Pharmaceutical Sciences,
2023
DOI:10.1007/s40199-023-00485-9
|
|
|
|
|
[2]
|
Challenges in Breast Cancer Control in Malaysia
Current Women s Health Reviews,
2022
DOI:10.2174/1573404817666210322153238
|
|
|
|
|
[3]
|
Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review
The Oncologist,
2021
DOI:10.1002/onco.13841
|
|
|
|
|
[4]
|
Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
BMC Health Services Research,
2021
DOI:10.1186/s12913-021-06277-8
|
|
|
|
|
[5]
|
From Evidence to Policy: Economic Evaluations of Healthcare in Malaysia - A Systematic Review
Value in Health Regional Issues,
2020
DOI:10.1016/j.vhri.2019.09.002
|
|
|
|
|
[6]
|
From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand
Value in Health Regional Issues,
2019
DOI:10.1016/j.vhri.2018.08.004
|
|
|
|
|
[7]
|
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics
Future Oncology,
2019
DOI:10.2217/fon-2019-0368
|
|
|
|
|
[8]
|
The Cost and Quality of Life of Malaysian Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease and Anemia
Value in Health Regional Issues,
2018
DOI:10.1016/j.vhri.2017.06.002
|
|
|
|
|
[9]
|
Administration de trastuzumab par voie sous-cutanée à domicile : retour d’expérience des patientes traitées en 2016 par l’hospitalisation à domicile Santé Service
Bulletin du Cancer,
2018
DOI:10.1016/j.bulcan.2018.10.005
|
|
|
|
|
[10]
|
Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs
Journal of Medical Economics,
2017
DOI:10.1080/13696998.2017.1285306
|
|
|
|